InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.44
(
0.74%
)
Bitcoin
63,861.24
(
0.38%
)
Post# of 50897
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mick

Send PM Follow Ignore
Followers 3158
Posts 964048
Boards Moderated 195
Alias Born 09/04/2000

mick

Member Level

Re: mick post# 48439

Friday, 03/27/2020 1:10:19 PM

Friday, March 27, 2020 1:10:19 PM

Post# of 50897
ABUS reports interim phase-1 data on AB-729 for HBV:

https://finance.yahoo.com/news/arbutus-announces-positive-preliminary-phase-200510591.html

AB-729 is an injected RNAi agent that targets HBsAg. The data reported today are from a single subcutaneous dose.

After 29 days, the mean reduction in HBsAg was: 0.2 logs in the 60mg cohort; and 0.8 logs in the 180mg cohort.

After 12 weeks, the mean reduction in HBsAg was: n/a in the 60mg cohort; and -1.0 logs in the 180mg cohort.

Whether HBsAg is the right target to be hitting is somewhat controversial—see, for instance, #msg-152274693.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up